Evermil 5 mg – Composition, Uses and Medicine Enquiries
Product Overview
Evermil 5 mg is a product listed under the anticancer category and is classified as an mTOR inhibitor.
Its active composition is Everolimus 5 mg.
It is associated with selected advanced cancers, including specific kidney, breast and neuroendocrine tumours.
The medicine blocks mTOR signalling that supports abnormal cell growth and division.
Suitability depends on the diagnosis, approved labeling, clinical history and specialist assessment.
This information is provided for education and product identification, not as a recommendation to begin treatment.
The master sheet calls this a transplant drug; however, the 5 mg oncology presentation must not be confused with transplant formulations.
A qualified clinician should confirm whether this exact brand, strength and formulation are appropriate before any prescription or treatment decision.
Composition and Strength
The supplied product information identifies the following composition:
| Active Ingredient | Strength |
|---|---|
| Everolimus | 5 mg |
Product Name: Evermil 5 mg
Generic Name: Everolimus
Brand Name: Evermil
Strength: 5 mg
Please verify the exact strength, dosage form, product labeling and manufacturer details against the original product packaging before publishing this product page or proceeding with an enquiry.
The 5 mg oncology presentation must not be conflated with transplant formulations.
Therapeutic Category and Indication
Evermil 5 mg belongs to the anticancer medicine category and is classified as an mTOR inhibitor.
Its principal clinical use is associated with selected advanced cancers, including specific kidney, breast and neuroendocrine tumours.
The active ingredient blocks mTOR signalling that supports abnormal cell growth and division.
Treatment eligibility may depend on diagnostic tests, organ function, other medicines and the relevant national prescribing information.
The original spreadsheet category or indication may not accurately represent the brand-specific approval. A qualified pharmacist should check the approved product label before publication.
The master sheet calls this a transplant drug; the 5 mg oncology presentation must not be confused with transplant formulations.
Administration Information
Evermil 5 mg is supplied as an oral tablet according to the provided product information.
The tablet should be taken consistently with or without food as prescribed by the oncology team.
Patients should follow the exact prescribed route, dose and schedule.
Do not change, share or discontinue this medicine without the treating professional’s advice.
Patients should also review the manufacturer’s patient instructions.
Product Presentation and Availability
The product enquiry can be made using the following details:
- Product Name: Evermil 5 mg
- Generic Name: Everolimus
- Brand Name: Evermil
- Strength: 5 mg
- Therapeutic Category: Anticancer
- Medicine Class: mTOR Inhibitor
- Indication: Selected advanced cancers, including specific kidney, breast and neuroendocrine tumours.
- Dosage Form: Oral Tablets.
- Route of Administration: Oral.
The master spreadsheet lists Glenmark as manufacturer/marketer. This attribution and the current pack size, dosage form, labeling, batch details and expiry must be independently verified.
No particular packaging, stock or delivery is promised by Medinglobal.
Prescription and Patient Safety
Evermil 5 mg is a prescription anticancer medicine requiring appropriate specialist supervision.
Treatment suitability depends on the diagnosis, approved labeling, clinical history and specialist assessment.
The 5 mg oncology presentation must not be confused with transplant formulations.
Patients should follow the oncology team’s instructions and should not independently change, share or discontinue the medicine.
The exact precautions, monitoring requirements and possible adverse effects should be checked against the current approved product information.
Medicine Enquiry Coordination Through Medinglobal
Medinglobal receives enquiries about Evermil 5 mg and may coordinate requests for product information with independent, appropriately authorised pharmaceutical providers.
Medinglobal is not the manufacturer, direct seller, dispensing pharmacy or exporter of this product.
Any permitted transaction, prescription check, destination-country assessment, supply terms and supporting documentation are handled by the relevant authorised provider.
An enquiry does not guarantee availability or supply.
How to Submit an Evermil 5 mg Enquiry
To help identify the requested product, include the following details when submitting an enquiry:
- Product or brand name: Evermil 5 mg.
- Generic name: Everolimus.
- Required strength and formulation.
- Required quantity.
- Destination country.
- Valid prescription or institutional documents, when required.
Medinglobal may connect the enquiry with an appropriately authorised independent provider, which must independently confirm legality, product identity and any applicable commercial terms.
Frequently Asked Questions
What is Evermil 5 mg used for?
It is associated with selected advanced cancers, including specific kidney, breast and neuroendocrine tumours, subject to the exact approved label and medical assessment.
What does Evermil 5 mg contain?
It contains Everolimus 5 mg. The final composition should be confirmed against the manufacturer’s product packaging.
How is Evermil 5 mg administered?
It is taken orally as a tablet, consistently with or without food as prescribed by the oncology team.
Is Evermil 5 mg an oncology or transplant medicine?
The supplied product information identifies Evermil 5 mg as an anticancer medicine and an mTOR inhibitor. Its 5 mg oncology presentation must not be confused with transplant formulations.
Can I request product information through Medinglobal?
Yes. Medinglobal can coordinate product information enquiries, but supply is neither guaranteed nor directly undertaken by Medinglobal.




Reviews
There are no reviews yet.